Article

Conventional Therapies Do Not Prolong the Prognosis of Hepatocellular Carcinoma Patients with Extrahepatic Metastases Under Receiving of Tyrosine Kinase Inhibitors

Hiroshi Maeda 1, Kouichi Miura 1,*, Naoki Morimoto 1, Shunji Watanabe 1, Mamiko Tsukui 1, Yoshinari Takaoka 1, Hiroaki Nomoto 1, Rie Goka 1, Naoto Sato 1, Kazue Morishima 2, Yasunaru Sakuma 2, Naohiro Sata 2, Noriyoshi Fukushima 3, Norio Isoda 1 and Hironori Yamamoto 1

1 Department of Medicine, Division of Gastroenterology, Jichi Medical University, 3311-1 Yakushiji Shimotsuke, Tochigi 329-0048, Japan; r1039hm@jichi.ac.jp (H.M.); morimoto@jichi.ac.jp (N.M.); 95103sw@jichi.ac.jp (S.W.); tsukui@jichi.ac.jp (M.T.); r0830yt@jichi.ac.jp (Y.T.); r0843hn@jichi.ac.jp (H.N.); md4027rg@jichi.ac.jp (R.G.); r1320hn@jichi.ac.jp (N.S.); isodano1@jichi.ac.jp (N.I.); ireef@jichi.ac.jp (H.Y.)
2 Department of Surgery, Division of Gastrointestinal, General and Transplant Surgery, Jichi Medical University, 3311-1 Yakushiji Shimotsuke, Tochigi 329-0048, Japan; morishima@jichi.ac.jp (K.M.); naruchan@jichi.ac.jp (Y.S.); sata2018@jichi.ac.jp (N.S.)
3 Department of Pathology, Jichi Medical University, 3311-1 Yakushiji Shimotsuke, Tochigi 329-0048, Japan; nfukushima@jichi.ac.jp
* Correspondence: miura385@jichi.ac.jp; Tel.: +02-85-58-7348 (ext. 329-0049)

Citation: Maeda, H.; Miura, K.; Morimoto, N.; Watanabe, S.; Tsukui, M.; Takaoka, Y.; Nomoto, H.; Goka, R.; Sato, N.; Morishima, K.; et al. Conventional Therapies Do Not Prolong the Prognosis of Hepatocellular Carcinoma Patients with Extrahepatic Metastases Under Receiving of Tyrosine Kinase Inhibitors. Cancers 2022, 14, 752. https://doi.org/10.3390/cancers14030752

Academic Editor: Dimitrios Moris
Received: 24 December 2021
Accepted: 28 January 2022
Published: 31 January 2022

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Copyright: © 2022 by the authors. License MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

Simple summary: Tyrosine kinase inhibitors (TKIs), including sorafenib and lenvatinib, have been the current standard treatment for advanced hepatocellular carcinoma (HCC) in cases where an immune checkpoint inhibitor cannot be used. The SHARP study showed that sorafenib tended to be less effective for extrahepatic metastases than for vascular invasion. Moreover, lenvatinib showed a response similar to that of sorafenib in such patients. The aforementioned data suggested that the addition of conventional therapies, including chemoembolization and radiation therapy, may improve the prognosis of such patients. Our retrospective study found that TKI promoted a longer overall survival in patients with extrahepatic metastases compared to conventional therapies. TKI plus conventional therapies did not promote a better prognosis compared to TKI alone. Thus, conventional therapies can be an option when events that worsen the quality of life occur in HCC patients with extrahepatic metastases.

Abstract: Background: Conventional therapies, including chemoembolization and radiation therapy, have been expected to prolong the prognosis of hepatocellular carcinoma (HCC) patients with extrahepatic metastases, which remains poor. However, little information is available on the efficacy of conventional therapies for such patients under tyrosine kinase inhibitor (TKI) treatment. Methods: We retrospectively investigated 127 HCC patients with extrahepatic metastases, who were divided into the non-TKI (conventional therapies) and TKI groups and further subdivided into the TKI alone and TKI plus conventional therapies groups. Conventional therapies included transcatheter arterial chemoembolization, cisplatin-based chemotherapy, radiation, surgery, and UFT, an oral chemotherapeutic agent. Results: The median of the overall survival (OS) of the 127 patients with extrahepatic metastases was 7.0 months. Meanwhile, the median OS of the TKI and non-TKI groups was 12.1 and 4.1 months, respectively. Imitating TKI after diagnosing metastases promoted a favorable increase in OS. Among the TKI group, the median OS in the TKI alone group was 8.9 months. TKI plus conventional therapies promoted no improvement in OS after adjusting for the patients’ background data. Conclusion: TKI promoted a better OS in HCC patients with extrahepatic metastases compared to conventional therapies. However, TKI plus conventional therapies promoted no improvement in the prognosis of such patients.
Keywords: hepatocellular carcinoma; extrahepatic metastases; prognosis; tyrosine kinase inhibitor; conventional therapy

1. Introduction

Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third leading cause of cancer death worldwide. In 2020, 905,677 new cases and 830,180 deaths had been reported according to a global cancer report [1]. Thus, the World Health Organization has sought to reduce the number of patients with HCC. Given that HCC is characterized by multi-focal cancer, it often recurs even after curative treatments, including surgical resection and radiofrequency ablation. Finally, HCC can progress to advanced stages, featuring major vessel invasion and/or extrahepatic metastases. Notably, the prognosis of patients whose HCC has progressed to the advanced stages is extremely poor.

Current standard treatments for advanced HCC include tyrosine kinase inhibitors (TKIs) and a combination of atezolizumab and bevacizumab, an immune checkpoint inhibitor (ICI) and a monoclonal antibody against vascular endothelial growth factor (VEGF), respectively. Before TKIs and ICI were available, patients with extrahepatic metastases were treated with conventional methods, including resection, radiation, and chemotherapies through the hepatic artery. Considering that intrahepatic lesions are a key prognostic factor, transcatheter arterial chemoembolization (TACE) and/or cisplatin-based chemotherapy had often been used. Indeed, reports have shown that cisplatin-based chemotherapy prolonged the prognosis of patients with advanced HCC [2,3]. When the primary lesions are well controlled, surgical resection can be performed for extrahepatic metastases, including the lungs, lymph nodes, and adrenal glands [4–6]. Radiation therapy for bone metastases has been reported to improve the prognosis [7]. However, the median survival time of patients with extrahepatic metastases has been reported to be 4.9–7.0 months, with a 1-year survival rate of 21.7–24.9% [8,9].

The first large study on sorafenib for patients with advanced HCC (the SHARP study) showed a median survival time of 10.7 months, which was significantly longer than that of the placebo [10]. Meanwhile, the first large study on lenvatinib (the REFLECT study) found a median survival time of 13.6 months, which was not inferior to that of sorafenib [11]. Thus, either sorafenib or lenvatinib has been used at the first-line TKI for advanced HCC. Although sorafenib started as the standard treatment for patients with advanced HCC, the SHARP study found that sorafenib tended to be less effective against extrahepatic metastases than against vascular invasion [10]. This trend was also noted in an analysis on Asian-Pacific patients [12]. Moreover, lenvatinib had a response that was similar to that of sorafenib in the treatment for HCC involving portal vein and/or extrahepatic spread. Although patients with extrahepatic metastases seemed to have longer OS after sorafenib was available [13], detailed information focusing on extrahepatic metastases was lacking. Furthermore, the outcomes of patients who received conventional therapies under TKI treatments remain unknown.

The present study therefore aimed to compare (1) TKI versus conventional therapies, (2) TKIs alone versus TKI plus conventional treatments, and (3) sorafenib versus lenvatinib, as well as determine (4) the efficacy of TKI against extrahepatic lesions in HCC patients with extrahepatic metastases. To this end, we retrospectively investigated the OS of HCC patients with extrahepatic metastases who received TKIs and conventional therapies.
2. Materials and Methods

2.1. Patients and Study Design

We retrospectively investigated 825 patients with HCC who visited Jichi Medical University Hospital from 1 May 2009 to 31 December 2019. During the study period, 127 cases with extrahepatic metastases were identified. No exclusion criteria were established. The overall survival (OS) and 1 and 3 year survival rates were assessed from the date at which extrahepatic metastases were detected until death from any cause. Performance status was determined according to Eastern Cooperative Oncology Group score. This study was approved by the ethics committee of Jichi Medical University (A19-154). All procedures followed have been performed in accordance with the ethical standards stated in the 1964 Declaration of Helsinki and its later amendments.

2.2. Diagnosis of HCC and Extrahepatic Metastases

HCC was diagnosed by hepatologists and radiologists using contrast-enhanced computed tomography and/or magnetic resonance imaging. Histologically proven HCC were also included. Moreover, positron emission tomography, bone scintigraphy, and X-ray examinations were used to diagnose extrahepatic metastases. Vascular invasion was defined as invasion of the portal vein (≥Vp1), hepatic vein (≥Vv1), and inferior vena cava on CT examinations.

2.3. Treatment and Responses

In the present study, 67 patients received TKI, including sorafenib and lenvatinib, as their first-line treatment. Conventional therapies included TACE, cisplatin-based chemotherapy using transcatheter arterial infusion (TAI), radiation, resection, and oral UFT (a combination of tegafur and uracil). In TACE, epirubicin hydrochloride, miriplatin hydrate, and cisplatin were used with ethyl ester of iodinated poppy-seed oil fatty acid (lipiodol®). Treatment decisions were made by each investigator. Patients who received TKI continued the therapy until the occurrence of grade 2 or higher adverse events (CTGAE, version 5.0 criteria), progressive disease (PD) according to Response Evaluation Criteria in Solid Tumors (RECIST), or death. Treatment response was evaluated as complete response (CR), partial response (PR), stable disease (SD), and PD based on RECIST version 1.1 [14]. Disease control rate (DCR) was a sum of CR, PR, and SD. Although imaging examinations were not always performed routinely, the first imaging test after the diagnosis of extrahepatic metastases was used for the assessment of efficacy. For the assessment of extrahepatic metastases, the maximum size of tumor was evaluated according to RECIST version 1.1.

2.4. Statistical Analysis

Patient background data were analyzed using the chi-square test, t-test, and Mann-Whitney test. Cumulative survival rates were assessed using the Kaplan–Meier survival curve, and differences were evaluated using the log rank test. Statistical analyses were performed using Stata/IC 15.1 (STATA Corporation, College Station, TX, USA), with p values < 0.05 indicating statistical significance.

3. Results

3.1. Characteristics of Patients with HCC Diagnosed with Metastases

Among the 825 patients with HCC, 127 (15.4%) were diagnosed with extrahepatic metastases (Table 1). The median age of the patients with extrahepatic metastases, 80.3% of whom were men, was 69.4 years old. The most common etiology was HCV, followed by HBV and alcohol. No significant differences in etiologies were observed between patients with and without metastases (data not shown). During the study period, a total of 167 extrahepatic metastatic sites were noted, with the most frequent organ involved being the bones (56 sites,
33.5%), followed by the lymph nodes (50 sites, 30.0%), lungs (47 sites, 28.1%), and adrenal glands (7 sites, 4.2%).

**Table 1.** Characteristics of patients with hepatocellular carcinoma upon diagnosis of metastases.

| Number                          | 127 |
|--------------------------------|-----|
| Age (years old)                | 69.4 (25.4–87.0) |
| Men                            | 102 (80.3%) |
| HBV/HCV/HBV + HCV              | 19 (15.0%)/69 (54.3%)/3 (2.4%) |
| Alcoholic/NASH/Others          | 15 (11.8%)/12 (9.4%)/9 (7.1%) |
| FIB4–index                     | 5.07 (0.48–39.5) |
| Child–Pugh score               | 6 (5–13) |
| ALBI score                     | −2.15 (−3.26 to −0.62) |
| AFP (ng/mL)                    | 155 (1–671,940) |
| DCP (mAU/mL)                   | 575 (10–1,084,600) |
| Frequency of multiple intrahepatic HCC | 95 (74.8%) |
| Maximum size of intrahepatic HCC (mm) | 44 (0–154) |
| Vascular invasion              | 80 (63.0%) |
| Hepatic TNM                    | 4 (0–4) |
| Performance status             | 0 (0–4) |
| Number of metastatic sites     | 167 |
| Bone/Lymph node/Lung/Adrenal glands/Peritoneum/Others | 56 (33.5%)/50 (30.0%)/47 (28.1%)/7 (4.2%)/4 (2.4%)/3 (1.8%) |

AFP, α-fetoprotein; DCP, des-γ-carboxy prothrombin; HBV, hepatitis B virus; HCV, hepatitis C virus; NASH, nonalcoholic steatohepatitis; TNM, tumor-node-metastasis.

3.2. Prognosis of Patients with Extrahepatic Metastases

We then investigated the OS of the 127 patients with extrahepatic metastases. During the study period, 103 patients died, 19 survived, and 5 were unknown. The median OS of all patients with extrahepatic metastases was 7.0 months, with 1 and 3 year survival rates of 36.4% and 7.9%, respectively (Figure 1).

![Figure 1. Cumulative survival rate of 127 HCC patients with extrahepatic metastases. Survival rates of all patients with extrahepatic metastases at 1 and 3 years were 36.4% and 7.9%, respectively. In treatment group, survival rates at 1 and 3 years were 43.5% and 8.6%, respectively. In the non-treatment group, survival rates at 1 and 3 years were 15.5% and 7.8%, respectively.](image)

Among the 127 patients with extrahepatic metastases, 96 received treatments, including TKI and/or conventional therapies, whereas the remaining 31 received no treatment. Those who received no treatment had a significantly shorter OS than those who did (p < 0.001). The median OS in the treatment and no treatment groups were 8.4 and 2.8 months, respectively, partially due to the unfavorable conditions in the no treatment group, including a poor liver function reserve and an advanced HCC stage (Table S1).
3.3. Prognosis of Patients Who Received TKIs

We then investigated the effects of treatments in patients with extrahepatic metastases. Accordingly, the 96 patients who received treatments were divided into the TKI group (TKI alone or TKI plus conventional therapies) and non-TKI group (conventional therapies). Two patients who received pembrolizumab or ramucirumab were excluded from the TKI group. Moreover, four patients who received TKIs before the occurrence of metastases were excluded from non-TKI group. Thus, we compared the OS between 65 patients in the TKI group and 25 patients in the non-TKI group. Details regarding the TKI and conventional therapies are shown in Table S2. The median OS in the TKI and non-TKI groups were 12.1 and 4.1 months, respectively, the difference being statistically significant (Figure 2a). Although the TKI group had a significantly superior prognosis compared to the non-TKI group, patients in the TKI group had a more favorable condition, including a liver function reserve (Table S3). To adjust for the patient’s background data, we analyzed the OS among patients with Child–Pugh classes A and B. The TKI group had a significantly longer OS than the non-TKI group, even after adjusting for the patient background (Figure 2b,c, Table 2). Among the 65 patients in the TKI group, 56 started TKI after the diagnosis of extrahepatic metastases. Patients who started TKI after having been diagnosed with extrahepatic metastases had a significantly longer median OS than those in the non-TKI group (Figure 2d). Moreover, the TKI group had a significantly superior OS compared to the non-TKI group among patients with Child–Pugh classes A and B (Figure 2e,f, Tables S4 and S5).

Table 2. Background data of patients in the TKI and non-TKI groups.

| Features | Child–Pugh A | Child–Pugh B |
|----------|--------------|--------------|
|          | TKI          | Non-TKI      | p-Value | TKI          | Non-TKI      | p-Value |
| Number   | 54           | 15           | 0.163    | 10           | 9            | 0.270    |
| Age (years old) | 69.6 (25.4−85.9) | 75.5 (61.8−83.4) | 0.002    | 72.5 (51.9−83.4) | 63.7 (49.6−87.0) | 0.027 |
| Men      | 44 (81.5%)   | 11 (73.3%)   | 0.548    | 9 (90.0%)    | 7 (77.8%)    | 0.466    |
| FIB-4 index | 3.94 (0.48−27.8) | 4.43 (1.74−14.3) | 0.490    | 6.42 (3.75−17.2) | 12.3 (3.58−25.7) | 0.125 |
| ALBI score | -2.49 (-3.25 to -1.50) | -2.38 (-3.26 to -1.65) | 0.258    | -1.87 (-2.21 to -1.19) | -1.77 (-2.44 to -0.90) | 0.606 |
| AFP (ng/mL) | 52 (1−128,650) | 155 (4−369,127) | 0.230    | 796 (2−123,578) | 577 (2−671,940) | 0.838 |
| DCP (mAU/mL) | 246 (10−1,084,600) | 166 (16−562,056) | 0.436    | 1066 (23−82,003) | 5952 (24−45,363) | 0.744 |
| Frequency of multiple intrahepatic HCC | 37 (68.5%) | 10 (66.7%) | 0.918    | 7 (70.0%) | 9 (100%) | 0.073 |
| Maximum size of intrahepatic HCC (mm) | 27 (0−154) | 41 (0−125) | 0.301    | 52 (0−127) | 53 (24−138) | 0.803 |
| Vascular invasion | 22 (40.7%) | 10 (66.7%) | 0.088    | 7 (70.0%) | 8 (88.9%) | 0.313 |
| Hepatic TNM | 3 (0−4) | 3 (0−4) | 0.162    | 3 (0−4) | 4 (3−4) | 0.030 |
| Performance status | 0 (0−3) | 0 (0−4) | 0.675    | 0 (0−2) | 0 (0−3) | 0.206 |

AFP, α-fetoprotein; DCP, des-γ-carboxy prothrombin; TKI, tyrosine kinase inhibitor; TNM, tumor-node-metastasis.
Figure 2. Cumulative survival rate of the non-TKI and TKI groups. (a–c) Patients with extrahepatic metastases who used TKI. (a) In the TKI group, survival rates at 1 and 3 years were 51.5% and 11.7%, respectively. In the non-TKI group, survival rates at 1 and 3 years were 13.1% and 0%, respectively. (b) Child–Pugh class A. In the TKI group, the survival rates at 1 and 3 years were 55.9% and 14.2%, respectively. In the non-TKI group, the survival rates at 1 and 3 years were 22.4% and 0%, respectively. (c) Child–Pugh class B. In the TKI group, the survival rates at 1 and 3 years were 33.8% and 0%, respectively. In the non-TKI group, the 1 year survival rate was 0%. (d–f) Patients who started TKI after being diagnosed with extrahepatic metastases. (d) The survival rate of the TKI group at 1 and 3 years were 51.4% and 12.6%, respectively. (e) Child–Pugh class A. The survival rates of the TKI group at 1 and 3 years were 56.5% and 15.7%, respectively. (f) Child–Pugh class B. The survival rates of the TKI group at 1 and 3 years were 33.3% and 0%, respectively.

3.4. Prognosis of Patients Who Received TKI Plus Conventional Therapies

Among the 65 patients in the TKI group, 36 received TKI plus conventional therapies. Although the TKI plus conventional therapies group tended to have a long OS, the difference was not significant (Figure 3a, Table 3). Then, we compared the OS in patients who met the REFLECT criteria (REFLECT IN) and did not meet the REFLECT criteria (REFLECT OUT) [11]. The major exclusion criteria were HCC occupation ≥50% of the liver, obvious invasion of the bile duct, or invasion at the main portal vein (Vp4). In the REFLECT IN, TKI plus conventional therapies had almost the same OS as the TKI alone group (Figure 3b). In the REFLECT OUT, although the TKI plus conventional therapies group tended to have a longer OS, the backgrounds of the patients were favorable (Figure
3c, Table S6). Considering that conventional therapies include several therapies, we separately evaluated TACE/TAI and radiation therapy. The TKI plus TACE/TAI group had almost the same OS as the TKI alone group (Figure 3d). Additionally, the TKI plus radiation group had the same OS as the TKI alone group (Figure 3e). Furthermore, TKI plus multiple conventional therapies did not prolong the OS even after adjusting for the patients’ background (data not shown). Oral UFT is a systemic chemotherapy, which may contribute to the OS in the TKI plus conventional therapies group. When patients who used oral UFT were excluded, the OS was similar between the TKI alone group and TKI plus conventional therapies group (data not shown). The majority of the patients in the TKI plus TACE/TAI group and TKI plus radiation group had lung metastases and bone metastases, respectively. No significant differences in prognosis were observed between those with lung metastases and bone metastases (Figure 3f and Table S7).

Table 3. Background data of patients who received TKI alone and TKI plus conventional therapies.

| Features                              | TKI Alone | TKI Plus Conventional Therapies | p-Value |
|---------------------------------------|-----------|---------------------------------|---------|
| Number                                | 29        | 36                              |         |
| Age (years old)                       | 71.1 (25.9–85.9) | 69.1 (49.9–85.1)              | 0.843   |
| Men                                   | 25 (86.2%) | 29 (80.6%)                      | 0.546   |
| FIB-4 index                           | 5.88 (0.95–18.0) | 3.93 (0.48–27.8)               | 0.240   |
| Child–Pugh score                      | 6 (5–11)  | 5 (5–8)                         | 0.293   |
| ALBI score                            | –2.32 (–3.20 to –0.90) | –2.43 (–3.25 to –1.19)         | 0.165   |
| AFP (ng/mL)                           | 169 (1–128,650) | 21 (11–23,578)                 | 0.083   |
| DCP (mAU/mL)                          | 395 (10–1,084,600) | 394 (15–63,989)                | 0.932   |
| Frequency of multiple intrahepatic HCC| 21 (72.4%) | 24 (66.7%)                      | 0.618   |
| Maximum size of intrahepatic HCC (mm) | 47 (0–154) | 24 (0–120)                      | 0.030   |
| Vascular invasion                     | 17 (58.6%) | 13 (36.1%)                      | 0.070   |
| Hepatic TNM                           | 3 (0–4)   | 2 (0–4)                         | 0.046   |
| Performance status                    | 0 (0–3)   | 0 (0–2)                         | 0.260   |

AFP, α-fetoprotein; DCP, des-γ-carboxy prothrombin; TKI, tyrosine kinase inhibitor; TNM, tumor–node–metastasis.
Figure 3. Cumulative survival rate. (a–c) TKI alone versus TKI plus conventional therapies. (a) All patients in TKI group. In the TKI alone group, survival rates at 1 and 3 years were 46.7% and 10.7%, respectively. In the TKI plus conventional therapies group, survival rates at 1 and 3 years were 55.0% and 12.6%, respectively. (b) REFLECT IN. In the TKI alone group, survival rates at 1 and 3 years were 61.8% and 12.1%, respectively. In the TKI plus conventional therapies group, survival rates at 1 and 3 years were 53.2% and 22.7%, respectively. (c) REFLECT OUT. In the TKI alone group, survival rates at 1 and 3 years were 32.4% and 8.1%, respectively. In the TKI plus conventional therapies group, survival rates at 1 and 3 years were 57.6% and 0%, respectively. (d) TKI alone versus TKI plus TACE/TAI. In the TKI plus TACE/TAI group, survival rates at 1 and 3 years were 45.3% and 27.3%, respectively. (e) TKI alone versus TKI plus radiation. In the TKI plus irradiation group, survival rates at 1 and 3 years were 42.4% and 0%, respectively. (f) Lung versus bone metastases. In the lung metastases group, survival rates at 1 and 3 years were 30.6% and 7.5%, respectively. In the bone metastases group, survival rates at 1 and 3 years were 40.7% and 5.1%, respectively.

3.5. Effect of Sorafenib and Lenvatinib in Patients with Extrahepatic Metastases

Among the 65 patients in the TKI group, 41 and 16 received sorafenib and lenvatinib, respectively, whereas the remaining 8 received two or three TKIs (Table 4). We initially compared the prognosis between the sorafenib and lenvatinib groups, both of which included TKI alone and TKI plus conventional therapies. No significant difference in prognosis was noted between the sorafenib and lenvatinib groups (Figure 4). Moreover, no significant difference in OS was observed between the sorafenib plus conventional therapies group (n = 17) and lenvatinib plus conventional therapies group (n = 12) (data not shown). The median treatment duration in patients receiving TKI, sorafenib, and lenvatinib was 4.1, 4.4, and 1.4 months, respectively. Adverse events and PD tended to be the most frequent cause for discontinuing lenvatinib and sorafenib treatment, respectively.
We also investigated the difference in OS between single and multiple TKIs. Although patients who received multiple TKIs tended to have a longer OS, no significant difference was observed after adjusting for the patient’s background (data not shown).

**Figure 4.** Cumulative survival rate of the sorafenib and lenvatinib groups. In the sorafenib group, survival rates at 1 and 3 years were 44.0% and 11.0%, respectively. In the lenvatinib group, survival rates at 1 and 3 years were 60.3% and 0%, respectively.

**Table 4.** Background data of patients who received sorafenib or lenvatinib.

| Features                        | Sorafenib Group | Lenvatinib Group | p-Value |
|---------------------------------|-----------------|------------------|---------|
| Number                          | 41              | 16               |         |
| Starting dose (mg)              |                 |                  |         |
| Sorafenib 200/400/600/800       | 8/21/2/10       | 6/4/6            |         |
| Lenvatinib 4/8/12               |                 |                  |         |
| Discontinuation dose            |                 |                  |         |
| Sorafenib 200/400/600/800       | 9/16/8/8        | 8/5/3            |         |
| Lenvatinib 4/8/12               |                 |                  |         |
| Age (years old)                 | 71.1 (25.4–85.9) | 67.8 (56.3–85.1) | 0.638   |
| Men                             | 35 (85.4%)      | 12 (75.0%)       | 0.355   |
| HBV                             | 5 (12.2%)       | 3 (18.8%)        | 0.522   |
| HCV                             | 22 (50.7%)      | 11 (68.8%)       | 0.300   |
| HBV + HCV                       | 2 (4.9%)        | 0 (0.0%)         | 0.368   |
| Alcoholic                       | 6 (14.6%)       | 0 (0.0%)         | 0.106   |
| NASH                            | 2 (4.9%)        | 1 (6.2%)         | 0.835   |
| Others                          | 4 (9.7%)        | 1 (6.2%)         | 0.674   |
| FIB-4 index                     | 5.09 (1.56–18.0) | 3.63 (0.48–14.7) | 0.192   |
| Child–Pugh score                | 5.5 (5/1)       | 5 (5–7)          | 0.341   |
| ALBI score                      | -2.42 (−3.25–0.90) | -2.43 (−2.96–1.19) | 0.986   |
| AFP (ng/mL)                     | 102 (1–128,650) | 62 (1–123,578)   | 0.379   |
| DCP (mAU/mL)                    | 488 (10–1,084,600) | 213 (18–63,989) | 0.965   |
| Frequency of multiple intrahepatic HCC | 30 (73.2%) | 10 (62.5%) | 0.429 |
| Maximum size of intrahepatic HCC (mm) | 45 (0–154) | 35 (0–137) | 0.449 |
| Vascular invasion               | 21 (51.2%)      | 6 (37.5%)        | 0.351   |
| Hepatic TNM                     | 3 (0–4)         | 3 (0–4)          | 0.394   |
| Performance status              | 0 (0–3)         | 0 (0–2)          | 0.334   |
| Reason of discontinuation PD/AE | 4.4 (0.2–40.9)  | 1.4 (0.2–26.9)   | 0.061   |
| TKI period                      | 14/24           | 2/14             | 0.074   |

AE, adverse event; AFP, α-fetoprotein; DCP, des-γ-carboxy prothrombin; HBV, hepatitis B virus; HCV, hepatitis C virus; NASH, nonalcoholic steatohepatitis; PD, progressive disease; TKI, tyrosine kinase inhibitor; TNM, tumor-node-metastasis.

### 3.6. Effect of TKIs on Extrahepatic Metastases

Among the 29 patients in the TKI alone group, 19 had data on the DCR of intrahepatic and extrahepatic lesions. We analyzed 19 intrahepatic lesions and 27 extrahepatic lesions in patients who used TKIs after the diagnosis of extrahepatic metastases. The DCRs of...
intrahepatic and extrahepatic lesions were 52.6% and 37.0%, respectively (Figure 5). No significant difference in efficacy was observed between intrahepatic and extrahepatic lesions ($p = 0.328$).

![Figure 5. Response to TKI. The efficacies of TKI for intrahepatic (n = 19) and extrahepatic lesions (n = 27) were separately evaluated. Numbers of each extrahepatic lesion are as follows; PR, LN (lymph node) 2, Other 1; SD, Bone 3, Lung 2, LN 1, Other 1; PD, Bone 2, Lung 8, LN 3, Other 4.](image)

4. Discussion

The present study demonstrated that TKI treatment provided a longer OS compared to conventional therapies. However, TKI plus conventional therapies did not prolong the prognosis compared to TKI alone. No significant difference in OS was observed between patients receiving sorafenib and lenvatinib. TKIs were as effective against extrahepatic metastases as with intrahepatic lesions.

The prognosis of patients with extrahepatic metastases still remained poor when TKI could be administered. The present study found that the median OS of patients with extrahepatic metastases was 7.0 months, which was almost equal to that in the pre-TKI era [8,15,16]. This is because 24% of patients did not receive any treatments for HCC given the poor hepatic function reserve and/or performance status at the time of extrahepatic metastases. Additionally, 20% of the patients received conventional therapies used in the pre-TKI era. Indeed, the median OS of patients in the no treatment group and non-TKI group were 2.8 and 4.1 months, respectively. Thus, nearly half of the patients in the present study could be characterized as being in a situation similar to that of the pre-TKI era. Our group had often used conventional therapies according to the patient’s requests just after sorafenib was available. However, our data showed that, among HCC patients with extrahepatic metastases, the non-TKI group (conventional therapies group) had a significantly inferior prognosis compared to the TKI group.

In contrast to the pre-TKI era, the present study showed higher 1 and 3 year survival rates in patients with extrahepatic metastases compared to previous reports [8,15]. We believe that these survival rates were caused by the TKI group, which had 1and 3 year survival rates of 51.5% and 11.7%, respectively. Moreover, our data showed that the TKI group had a median OS of 12.1 months, which agreed with the previous reports after sorafenib was available wherein the median OS was 10.3–11 months [13,17]. In a comparison of the OS, we had to pay attention to eligible criteria because they varied among studies. When we adjusted the eligible criteria to the REFLECT study [11], the median OS of patients with extrahepatic metastases in our study was 15.8 months, which was longer than that of the REFLECT study (sorafenib 9.8 months, lenvatinib 11.5 months). However, the number of patients in our study was small compared to that of the REFLECT study ($n = 14$ versus $n = 329–336$). TKI alone provided a similar DCR of intrahepatic and extrahepatic metastases.
lesions. The TACTICS trial [18] revealed that sorafenib plus TACE promoted a significantly better progression-free survival of patients with unresectable HCC compared to TACE alone. Although the TACTICS trial did not include patients with extrahepatic metastases, sorafenib prolonged the development of major vascular invasion and extrahepatic metastases. These data suggested that TKIs can prolong the prognosis of HCC by delaying the progression of HCC, including extrahepatic metastases.

Our data showed that the combination of TKI and conventional therapies provided no significant benefit in prognosis compared to TKI alone. It is of interests that conventional therapies contributed to the prognosis under TKI treatment. In the SHARP [10] and the REFLECT studies [11], patients with favorable conditions, such as Child–Pugh class A, were enrolled in the clinical trials. However, we frequently encounter patients who do not meet the eligible criteria of such studies due to a “far advanced stage” in clinical practice. Although TKI plus conventional therapies tended to have a longer OS than TKI alone in the “far advanced stage”, here defined as REFLECT OUT, our data failed to show a prolonged prognosis. Among conventional therapies, TACE/TAI has been used to control intrahepatic HCC, even in patients with extrahepatic metastases, given that the intrahepatic tumor stage has been identified as a prognostic factor [8]. Previous retrospective studies have reported that cisplatin-based chemotherapy via a catheter can prolong the prognosis of patients with advanced HCC [2,3]. In contrast, a prospective study revealed that sorafenib plus cisplatin-based chemotherapy failed to improve the prognosis of patients with advanced HCC compared to those treated with sorafenib alone [19]. Considering that extrahepatic metastatic lesions were noted at multiple sites, we investigated the OS provided by each treatment, namely TKI plus TACE/TAI, TKI plus radiation therapy, and TKI plus multiple conventional therapies. These data suggested that conventional therapies did not provide sufficient prognostic benefits among patients with extrahepatic metastases, particularly with regard to controlling intrahepatic and extrahepatic lesions.

Our study included patients treated with lenvatinib, which may have contributed to the favorable prognosis of patients with extrahepatic metastases. However, there was no significant difference in the OS between sorafenib and lenvatinib groups. Although lenvatinib has been reported to promote a longer progression-free survival compared to sorafenib, the OS between sorafenib and lenvatinib in patients with advanced HCC was almost equal [20,21]. Currently, limited data are available on the comparison of these TKIs in patients with extrahepatic metastases. Our data showed no superiority of lenvatinib over sorafenib for patients with extrahepatic metastases. However, the majority of the patients of the TKI group received sorafenib (75%, 49 patients). Moreover, the treatment duration of lenvatinib was short due to adverse events. Further investigations are required to clarify this matter.

In the present study, the most common site of extrahepatic metastases was the bones. According to previous reports, the most common site of extrahepatic metastases was the lungs [15,16,22]. This could have been partly attributed to the characteristics of our hospital, in which, patients with bone metastases are referred for radiation therapy. Although some reports demonstrated that bone metastases had a better prognosis compared to other metastatic sites, [23,24] mixed data have been reported regarding the prognosis among metastatic sites [25]. Notably, our data showed no significant difference between bone and lung metastases.

The present study has a few limitations worth noting. Given the retrospective nature of this study and our inclusion of extrahepatic lesions, conventional therapies included multiple modalities, single to multiple sessions, and combinations thereof. Indeed, some patients had huge intrahepatic lesions and multiple sites of extrahepatic metastases. In these cases, TACE was added to prevent the rupture of the HCC. In addition, radiation therapy for bone metastases was added to relieve pain. As such, it was difficult to compare the efficacy between a single therapy and TKI, which should have been ideal. The present study failed to show any favorable results for the use of conventional therapies. However,
we do not always deny the use of conventional therapies, which can be one option in the event that the quality of life worsens.

The recently IMbrave150 study demonstrated that the effects of an ICI coupled with a VEGF inhibitor were superior to that of sorafenib in patients with advanced HCC [26]. In patients with extrahepatic metastases, the atezolizumab plus bevacizumab had a longer survival than sorafenib (median OS, 17.8 versus 10.4 month) [27]. Thus, treatment with an ICI coupled with a VEGF inhibitor has recently become the standard treatment for patients with extrahepatic metastases. Although the eligible criteria between the IMbrave150 study and our study are different, the median OS of our subgroups (14.8 months in Child–Pugh class A, Figure 2b, 15.8 months in REFLECT IN, Figure 3b) was close to that of the IMbrave150 study. In a retrospective study, a triple combination of an ICI, TKI, and TACE showed favorable outcomes compared with a dual combination of an ICI and TKI [28]. Currently, multiple clinical trials are taking place using ICI-based therapies, which include a conventional therapy such as TACE, for unresectable HCC (https://clinicaltrials.gov/ct2/home, accessed on January 17, 2022). Our study may highlight the position of conventional therapies in the era of ICI therapy. Further studies are nonetheless necessary to determine the best treatment option for HCC patients with extrahepatic metastases.

5. Conclusion

TKI promoted a better prognosis in HCC patients with extrahepatic metastases compared to conventional therapies. Conventional therapies did not prolong the prognosis of HCC patients with extrahepatic metastases under the receiving of tyrosine kinase inhibitors.

Supplementary Materials: The following supporting information can be downloaded at: www.mdpi.com/2072-6694/14/3/752/s1, Table S1: Background data of patients in the treatment and no treatment groups, Table S2: Contents of TKI and conventional therapies, Table S3: Background data of patients in TKI and non-TKI groups, Table S4: Background data of patients who started TKI after diagnosis of metastases, Table S5: Background data of Child-Pugh A and B patients who started TKI after diagnosis of metastases, Table S6: Background data of patients who meet the REFLECT criteria (REFLECT IN) and do not meet the criteria (REFLECT OUT), Table S7: Background data of patients with lung or bone metastases.

Author Contributions: Conceptualization, H.M., K.Mi. and N.M.; methodology, H.M., K.Mi. and N.M.; software, H.M., K.Mi. and N.M.; validation, H.M., K.Mi. and N.M.; formal analysis, H.M., K.Mi. (Kouichi Miura), and N.M.; investigation, H.M., K.Mi., N.M., S.W., M.T., Y.T., H.N., R.G., N.Sato, K.Mo., Y.S., N.Sata, N.F., N.I., and H.Y.; resources, K.Mi., N.M., and N.I.; data curation, H.M., K.Mi., and N.M.; writing—original draft preparation, H.M., writing—review and editing, K.Mi.; visualization, H.M.; supervision, N.Sata, N.I., and H.Y.; project administration, K.Mi.; funding acquisition. All authors have read and agreed to the published version of the manuscript.

Funding: No authors received funds related to the present study.

Institutional Review Board statement: The present study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethic Committee of Jichi Medical University Hospital (A19-154).

Informed Consent statement: As a result of the retrospective nature of this study, the requirement of written informed consent was waived. Instead, opt-out consent documents were shown on the website of Jichi Medical University for patients who did not wish to participate in the study.

Data Availability Statement: The data are presented within the paper. Additional raw data are available on request from the corresponding author.

Conflicts of Interest: Honoraria for speaker at the symposium; Kouichi Miura from Sumitomo Dainippon and Chugai; Naoki Morimoto from Bayer, Eizai, Takeda, and Chugai; Shunji Watanabe from Sumitomo Dainippon and Eizai; Hiroaki Nomoto from Eizai and Chugai; Kazue Morishima from Eizai; Yasunaru Sakuma from Eizai; Naohiro Sata from Chugai; Noriyoshi Fukushima from Chugai and Takeda; Norio Isoda from Bayer, Sumitomo Dainippon, and Chugai; Hironori Yamamoto from Takeda. Research fees not related to the present study. Kouichi Miura from Sumitomo Dainippon, Eli Lilly, and Chugai; Naoki Morimoto from Eizai; Naohiro Sata from Chugai and
Takeda; Norio Isoda from Eizai; Hironori Yamamoto from Takeda. The companies mentioned above had no role in the design of the study, in the data collection, analyses, interpretation of data, writing of the manuscript, and decision to publish the results.

**Abbreviations**

CR complete response  
HCC hepatocellular carcinoma  
ICI immune checkpoint inhibitor  
PD progressive disease  
PR partial response  
RECIST Response Evaluation Criteria in Solid Tumors  
SD stable disease  
TACE transcatheater arterial chemoembolization  
TAI transhepatic arterial infusion  
TKI tyrosine kinase inhibitor  
TNM tumor-node-metastasis  
VEGF vascular endothelial growth factor

**References**

1. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F.; Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J. Clin.* 2021, 71, 209–249.
2. Kondo, M.; Morimoto, M.; Ishii, T.; Nozaki, A.; Fukuda, H. Original Article Hepatic Arterial Infusion Chemotherapy with Cisplatin and Sorafenib in Hepatocellular Carcinoma Patients Unresponsive to Transarterial Chemoembolization: A Propensity Score-Based Weighting. *J. Dig. Dis.* 2015, 16, 143–151. https://doi.org/10.1111/1751-2980.12221.
3. Kawaoka, T.; Aikata, H.; Hyogo, H.; Morio, R.; Morio, K.; Hatoooka, M.; Fukuwara, T.; Kobayashi, T.; Naeshiro, N.; Miyaki, D.; et al. Comparison of Hepatic Arterial Infusion Chemotherapy versus Sorafenib Monotherapy in Patients with Advanced Hepatocellular Carcinoma. *J. Dig. Dis.* 2015, 16, 505–512.
4. Berger, Y.; Spivack, J.H.; Heskel, M.; Aycart, S.N.; Labow, D.M.; Sarpel, U. Extrahepatic Metastasectomy for Hepatocellular Carcinoma: Predictors of Long-Term Survival. *J. Surg. Oncol.* 2016, 114, 469–474.
5. Lam, C.M.; Lo, C.M.; Yuen, W.K.; Liu, C.L.; Fan, S.T. Prolonged Survival in Selected Patients Following Surgical Resection for Pulmonary Metastasis from Hepatocellular Carcinoma. *Br. J. Surg.* 1998, 85, 1198–1200.
6. Joon, S.P.; Yoon, D.S.; Kim, K.S.; Choi, J.S.; Lee, W.J.; Chi, H.S.; Kim, B.R. What Is the Best Treatment Modality for Adrenal Metastasis from Hepatocellular Carcinoma? *J. Surg. Oncol.* 2007, 96, 32–36.
7. Hu, C.; Yang, J.; Huang, Z.; Liu, C.; Lin, Y.; Tong, Y.; Fan, Z.; Chen, B.; Wang, C.; Zhao, C.L. Diagnostic and Prognostic Nomograms for Bone Metastasis in Hepatocellular Carcinoma. *BMC Cancer* 2020, 20, 1–11.
8. Uka, K.; Aikata, H.; Takaki, S.; Shiraokawa, H.; Jeong, S.C.; Yamashina, K.; Hiramatsu, A.; Kodama, H.; Takahashi, S.; Chayama, K. Clinical Features and Prognosis of Patients with Extrahepatic Metastases from Hepatocellular Carcinoma. *World J. Gastroenterol.* 2007, 13, 414–420.
9. Aino, H.; Sumie, S.; Niizeki, T.; Kuromatsu, R.; Tajiri, N.; Nakano, M.; Satani, M.; Yamada, S.; Okamura, S.; Shimose, S.; et al. Clinical Characteristics and Prognostic Factors for Advanced Hepatocellular Carcinoma with Extrahepatic Metastasis. *Mol. Clin. Oncol.* 2014, 2, 393–398.
10. Llovet, J.M.; Ricci, S.; Mazzaferro, V.; Hilgard, P.; Gane, E.; Blanc, J.F.; de Oliveira, A.C.; Santoro, A.; Raoul, J.L.; Forner, A.; et al. Sorafenib in Advanced Hepatocellular Carcinoma. *N. Engl. J. Med.* 2008, 359, 378–390.
11. Kudo, M.; Finn, R.S.; Qin, S.; Han, K.H.; Ikeda, K.; Piscaglia, F.; Baron, A.; Park, J.W.; Han, G.; Jassem, J.B.; et al. Lenvatinib versus Sorafenib in First-Line Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Randomised Phase 3 Non-Inferiority Trial. *Lancet* 2018, 391, 1163–1173.
12. Cheng, A.L.; Kang, Y.K.; Chen, Z.; Tsao, C.J.; Qin, S.; Kim, J.S.; Luo, R.; Feng, J.; Ye, S.; Yang, T.S.; et al. Efficacy and Safety of Sorafenib in Patients in the Asia-Pacific Region with Advanced Hepatocellular Carcinoma: A phase III Randomised, Double-Blind, Placebo-Controlled Trial. *Lancet Oncol.* 2009, 10, 25–34.
13. Nakano, M.; Tanaka, M.; Kuromatsu, R.; Nagamatsu, H.; Tajiri, N.; Satani, M.; Niizeki, T.; Aino, H.; Okamura, S.; Iwamoto, H.; et al. Sorafenib for the Treatment of Advanced Hepatocellular Carcinoma with Extrahepatic Metastasis: A Prospective Multicenter Cohort Study. *Cancer Med.* 2015, 4, 1836–1843.
14. Eisenhauer, E.A.; Therasse, P.; Bogaerts, J.; Schwartz, LH.; Sargent, D.; Ford, R.; Dancey, J.; Arbuck, S.; Gwyther, S.; Mooney, M.; et al. New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1). *Eur. J. Cancer* **2009**, *45*, 228–247.

15. Natsuizaka, M.; Omura, T.; Akaike, T.; Kuwata, Y.; Yamazaki, K.; Sato, T.; Karino, Y.; Toyota, J.; Suga, T.; Asaka, M. Clinical Features of Hepatocellular Carcinoma with Extrahepatic Metastases. *J. Gastroenterol. Hepatol.* **2005**, *20*, 1781–1787.

16. Uchino, K.; Tateishi, R.; Shiina, S.; Kanda, M.; Masuzaki, R.; Kondo, Y.; Goto, T.; Omata, M.; Yoshida, H.; Koike, K. Hepatocellular Carcinoma with Extrahepatic Metastasis: Clinical Features and Prognostic Factors. *Cancer* **2011**, *117*, 4475–4483.

17. Kawaoaka, T.; Aikata, H.; Hyogo, H.; Morio, R.; Morio, K.; Hatooka, M.; Fukubara, T.; Kobayashi, T.; Naeshiro, N.; Miyaki, D.; et al. Clinical Outcome and Prognostic Factors of Patients with Hepatocellular Carcinoma and Extrahepatic Metastasis Treated with Sorafenib. *Hepatol. Res.* **2014**, *44*, 1320–1328.

18. Kudo, M.; Ueshima, K.; Ikeda, M.; Torimura, T.; Tanabe, N.; Aikata, H.; Izumi, N.; Yasamaki, T.; Nijiri, S.; Hino, K.; et al. Randomised, Multicentre Prospective Trial of Transarterial Chemoembolisation (TACE) Plus Sorafenib as Compared with TACE Alone in Patients with Hepatocellular Carcinoma: TACTICS Trial. *Gut* **2020**, *69*, 1492–1501. https://doi.org/10.1136/gutjnl-2019-318934.

19. Kudo, M.; Ueshima, K.; Yokosuka, O.; Ogasawara, S.; Obi, S.; Izumi, N.; Aikata, H.; Nagano, H.; Hatano, E.; Sasaki, Y.; et al. Sorafenib Plus Low-Dose Cisplatin and Fluorouracil Hepatic Arterial Infusion Chemotherapy versus Sorafenib Alone in Patients with Advanced Hepatocellular Carcinoma (SILIUS): A Randomised, Open Label, Phase 3 Trial. *Lancet Gastroenterol. Hepatol.* **2018**, *3*, 424–432.

20. Tomonari, T.; Sato, Y.; Tani, J.; Hirose, A.; Ogawa, C.; Morishita, A.; Tanaka, H.; Tanaka, T.; Taniguchi, T.; Okamoto, K.; et al. Comparison of Therapeutic Outcomes of Sorafenib and Lenvatinib as Primary Treatments for Hepatocellular Carcinoma with a Focus on Molecular-Targeted Agent Sequential Therapy: A Propensity Score-Matched Analysis. *Hepatol. Res.* **2021**, *51*, 472–481.

21. Kim, S.; Kim, K.H.; Kim, B.K.; Kim, S.U. Lenvatinib Is Independently Associated with the Reduced Risk of Progressive Disease When Compared with Sorafenib in Patients with Advanced Hepatocellular Carcinoma. *J. Gastroenterol. Hepatol.* **2021**, *36*, 1317–1325.

22. Kanda, M.; Tateishi, R.; Yoshida, H.; Sato, T.; Masuzaki, R.; Ohki, T.; Imamura, J.; Goto, T.; Yoshida, H.; Hamamura, K.; et al. Extrahepatic Metastasis of Hepatocellular Carcinoma: Incidence and Risk Factors. *Liver Int.* **2008**, *28*, 1256–1263.

23. Chen, J. The Prognostic Analysis of Different Metastatic Patterns in Advanced Liver Cancer Patients: A Population Based Analysis. *PLoS ONE* **2018**, *13*, e0200909.

24. Zhan, H.; Zhao, X.; Lu, Z.; Yao, Y.; Zhang, X. Correlation and Survival Analysis of Distant Metastasis Site and Prognosis in Patients With Hepatocellular Carcinoma. *Front. Oncol.* **2021**, *11*, 1–12.

25. Tsuchiya, K.; Kurosaki, M.; Sakamoto, A.; Marusawa, H.; Kojima, Y.; Hasebe, C.; Arai, H.; Joko, K.; Kondo, M.; Tsuji, K.; et al. The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study. *Cancer (Basel)* **2021**, *13*, 2608.

26. Finn, R.S.; Qin, S.; Ikeda, M.; Galle, P.R.; Duceux, M.; Kim, T.Y.; Kudo, M.; Breder, V.; Merle, P.; Kaseb, A.O.; et al. Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma. *N. Engl. J. Med.* **2020**, *382*, 1894–1905.

27. Cheng, A.L.; Qin, S.; Ikeda, M.; Galle, P.R.; Duceux, M.; Kim, T.Y.; Lim, H.Y.; Kudo, M.; Breder, V.; Merle, P.; et al. Updated Efficacy and Safety Data from IMbrave150: Atezolizumab Plus Bevacizumab vs. Sorafenib for Unresectable Hepatocellular Carcinoma. *J. Hepatol.* **2021**, https://doi.org/10.1016/j.jhep.2021.11.030.

28. Dai, L.; Cai, X.; Mugaanyi, J.; Liu, Y.; Mao, S.; Lu, C.; Lu, C. Therapeutic Effectiveness and Safety of Sintilimab-Dominated Triple Therapy in Unresectable Hepatocellular Carcinoma. *Sci. Rep.* **2021**, *11*, 1–12.